Administer the Wegovy pen 3 inches above the elbow and 3 inches below the shoulder
If constipation persists, discuss it with your WeightCare physician during your refill check-in
Because the data in the TriNetX platform is HIPAA de-identified, and therefore, by definition is deemed to allow no access to protected health information (and therefore no risk of protected health information disclosure), Institutional Review Boards (IRBs) have no jurisdiction of studies using HIPAA de-identified data 53
Zepbound (tirzepatide) - This dual-action medication targets both GLP-1 and GIP receptors, achieving remarkable results with up to 22.5% weight loss in clinical studies
Return peptides to the refrigerator as soon as possible
Blood Pressure Reduction: Users typically experience 4-8 mmHg systolic reductions, mediated by weight loss, salt sensitivity reduction, and improved endothelial function